Dyslipidemia: prevalence and association with precancerous and cancerous lesions of the cervix; a pilot study.
Cancerous lesions
Cervix
Dyslipidemia
Precancerous lesions
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
06 Jan 2024
06 Jan 2024
Historique:
received:
03
08
2023
accepted:
28
12
2023
medline:
7
1
2024
pubmed:
7
1
2024
entrez:
6
1
2024
Statut:
epublish
Résumé
In Sub-Saharan Africa, the prevalence of dyslipidemia is on the rise, with studies showing dyslipidemia as a contributing factor to the progression of premalignant lesions to cervical cancer. In Uganda, cervical cancer and dyslipidemia are common health concerns, considering the increasing trends of dyslipidemia in the general population and inadequate information regarding dyslipidemia and cervical lesions. This study aimed to determine the prevalence of dyslipidemia and its association with precancerous and cancerous lesions of the cervix among women attending a cervical cancer clinic at the Uganda Cancer Institute. This cross-sectional study was conducted from February to April 2022 among women with premalignant and malignant lesions of the cervix. Data on social demographics and health-seeking behaviours were collected using a pretested structured questionnaire after written informed consent had been obtained. Pap smear collection preceded visual inspection with acetic acid; cervical biopsies were collected appropriately from eligible participants; and cervical lesions were classified using the Bethesda system 2014. Serum lipids, total cholesterol (T.C.), high-density lipoprotein (HDLc), low-density lipoprotein (LDLc), and triglycerides (T.G.s) were analysed using the COBAS™ 6000 Clinical Chemistry Analyser. The associations were assessed using the chi-square test, and P ≤ 0.05 was considered statistically significant. The overall prevalence of dyslipidemia among women with cervical lesions was 118/159 (74%), and low HDLc was the most prevalent at 64.6% (95% CI 39.0-54.3). High T.C. (P = 0.05), high T.G.s (P = 0.011), and low HDL-c (P = 0.05) showed a significant association with precancerous lesions. High LDL-c (P = 0.019), high T.G.s (P = 0.02), and high T.G.s (P < 0.001) showed a statistically significant association with cancerous lesions. The prevalence of dyslipidemia was high, with high TC, T.G.s, and low HDL-c significantly associated with precancerous lesions. Also, elevated T.G.s and high LDLc were significantly associated with cancerous lesions. Women may benefit from dyslipidemia screening along with cervical cancer screening. The present study builds upon previous findings suggesting a link between dyslipidemia and cervical lesions by investigating the relationship between these two factors, specifically in women of this geographical location, where we need adequate information on these associations.
Sections du résumé
BACKGROUND
BACKGROUND
In Sub-Saharan Africa, the prevalence of dyslipidemia is on the rise, with studies showing dyslipidemia as a contributing factor to the progression of premalignant lesions to cervical cancer. In Uganda, cervical cancer and dyslipidemia are common health concerns, considering the increasing trends of dyslipidemia in the general population and inadequate information regarding dyslipidemia and cervical lesions. This study aimed to determine the prevalence of dyslipidemia and its association with precancerous and cancerous lesions of the cervix among women attending a cervical cancer clinic at the Uganda Cancer Institute.
METHODS
METHODS
This cross-sectional study was conducted from February to April 2022 among women with premalignant and malignant lesions of the cervix. Data on social demographics and health-seeking behaviours were collected using a pretested structured questionnaire after written informed consent had been obtained. Pap smear collection preceded visual inspection with acetic acid; cervical biopsies were collected appropriately from eligible participants; and cervical lesions were classified using the Bethesda system 2014. Serum lipids, total cholesterol (T.C.), high-density lipoprotein (HDLc), low-density lipoprotein (LDLc), and triglycerides (T.G.s) were analysed using the COBAS™ 6000 Clinical Chemistry Analyser. The associations were assessed using the chi-square test, and P ≤ 0.05 was considered statistically significant.
RESULTS
RESULTS
The overall prevalence of dyslipidemia among women with cervical lesions was 118/159 (74%), and low HDLc was the most prevalent at 64.6% (95% CI 39.0-54.3). High T.C. (P = 0.05), high T.G.s (P = 0.011), and low HDL-c (P = 0.05) showed a significant association with precancerous lesions. High LDL-c (P = 0.019), high T.G.s (P = 0.02), and high T.G.s (P < 0.001) showed a statistically significant association with cancerous lesions.
CONCLUSION
CONCLUSIONS
The prevalence of dyslipidemia was high, with high TC, T.G.s, and low HDL-c significantly associated with precancerous lesions. Also, elevated T.G.s and high LDLc were significantly associated with cancerous lesions. Women may benefit from dyslipidemia screening along with cervical cancer screening.
WHAT THIS STUDY ADDS
CONCLUSIONS
The present study builds upon previous findings suggesting a link between dyslipidemia and cervical lesions by investigating the relationship between these two factors, specifically in women of this geographical location, where we need adequate information on these associations.
Identifiants
pubmed: 38184564
doi: 10.1186/s12944-023-01997-8
pii: 10.1186/s12944-023-01997-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Informations de copyright
© 2024. The Author(s).
Références
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203.
doi: 10.1016/S2214-109X(19)30482-6
pubmed: 31812369
IARC IAfRoC. Cancer tomorrow. GLOBOCAN. 2020.
Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. Human papillomavirus and related diseases report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). 2019.
Aragones A, Bruno D, Gany F. Attitudes surrounding implementation of the HPV vaccine for males among primary care providers serving large minority populations. J Health Care Poor Underserved. 2013;24(2):768.
doi: 10.1353/hpu.2013.0088
pubmed: 23728043
pmcid: 5206910
Trim K, Nagji N, Elit L, Roy K. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstetr Gynecol Int. 2012;2012:1-13.
Institute NC. What Is Cervical Cancer? October 13, 2022; Available from: https://www.cancer.gov/ .
Organization W.H. Advocacy for cervical cancer prevention and control in Africa: facilitator manual. 2017.
Health WHOR, Organization W.H., Diseases WHOC, Promotion H. Comprehensive cervical cancer control: a guide to essential practice: World Health Organization; 2006.
Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer. 2014;135(2):453–66 Epub 2013/12/18.
doi: 10.1002/ijc.28666
pubmed: 24338632
Xu H, Egger S, Velentzis LS, O’Connell DL, Banks E, Darlington-Brown J, et al. Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30–44 years: a case-control study in New South Wales. Australia Cancer Epidemiol. 2018;55:162–9.
doi: 10.1016/j.canep.2018.05.013
pubmed: 29980028
IARC I. monographs vol. 100C Evaluation of carcinogenic risks to humans. International Agency for Research on Cancer, Lyon, France. 2012.
Cancer ICoESoC. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006;119(5):1108–24.
doi: 10.1002/ijc.21953
Ssedyabane F, Amnia DA, Mayanja R, Omonigho A, Ssuuna C, Najjuma JN, et al. HPV-chlamydial coinfection, prevalence, and association with cervical intraepithelial lesions: a pilot study at Mbarara regional referral hospital. J Cancer Epidemiol. 2019;2019:9092565.
doi: 10.1155/2019/9092565
pubmed: 30733803
pmcid: 6348791
Pappan N, Rehman A. Dyslipidemia. StatPearls [Internet]: StatPearls Publishing; 2022.
Raju K, Punnayanapalya SS, Mariyappa N, Eshwarappa SM, Anjaneya C, Kai LJ. Significance of the plasma lipid profile in cases of carcinoma of cervix: a tertiary hospital based study. Asian Pac J Cancer Prev. 2014;15(8):3779–84.
doi: 10.7314/APJCP.2014.15.8.3779
pubmed: 24870793
Danaei G, Singh GM, Paciorek CJ, Lin JK, Cowan MJ, Finucane MM, et al. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation. 2013;127(14):1493–502.
doi: 10.1161/CIRCULATIONAHA.113.001470
pubmed: 23481623
pmcid: 4181853
Oldewage-Theron WH, Egal AA. Prevalence of and contributing factors to dyslipidaemia in low-income women aged 18–90 in the peri-urban Vaal region. South Afr J Clin Nutr. 2013;26(1):23–9.
doi: 10.1080/16070658.2013.11734436
Grundy SJJCL. Expert Dyslipidemia Panel. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7(6):561–5.
Frontela-Noda M, Delgado-Herrera DC, Cabrera-Rode E, Hernández-Menéndez M, Durán-Bornot R, Villarreal-Acosta A, et al. Association between components of the metabolic syndrome and degree of cervical squamous intraepithelial lesions in Cuban women. Diab Metab Syndr. 2019;13(2):1443–8 Epub 2019/07/25.
doi: 10.1016/j.dsx.2019.02.011
Veghari G, Sedaghat M, Maghsodlo S, Banihashem S, Moharloei P, Angizeh A, et al. The association between abdominal obesity and serum cholesterol level. Int J Appl Basic Med Res. 2015;5(2):83.
doi: 10.4103/2229-516X.157150
pubmed: 26097812
pmcid: 4456899
Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006;169(5):1505–22.
doi: 10.2353/ajpath.2006.051090
pubmed: 17071576
pmcid: 1780220
Ahn HK, Shin JW, Ahn HY, Park CY, Lee NW, Lee JK, et al. Metabolic components and recurrence in early-stage cervical cancer. Tumour Biol. 2015;36(3):2201–7 Epub 2014/11/16.
doi: 10.1007/s13277-014-2831-y
pubmed: 25398694
Kushwah AS, Mishra R, Srivastava K, Mishra S, Banerjee M. Association of Dyslipidemia, Renal dysfunction, and Uricemia with HPV mediated Cervical Cancer. 2022.
Dey P. Basic and advanced laboratory techniques in histopathology and cytology: Springer; 2018.
Nayar R, Wilbur DCJAc. The pap test and Bethesda 2014. J Am Soc Cytopathol. 2015;59(2):121–32.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (E.S.C) and European Atherosclerosis Society (E.A.S). Eur Heart J. 2019;41(1):111–88.
doi: 10.1093/eurheartj/ehz455
Blanc-Lapierre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent M-É. Metabolic syndrome and prostate cancer risk in a population-based case–control study in Montreal, Canada. BMC Public Health. 2015;15(1):913.
doi: 10.1186/s12889-015-2260-x
pubmed: 26385727
pmcid: 4574395
Wang S, Zhang Y, Zhou X, Zhang K, Zhang Y, Yao Y, et al. High prevalence of overweight/obesity and dyslipidemia in patients with intracranial germ cell tumors. Pituitary. 2022;25(6):938–47.
doi: 10.1007/s11102-022-01274-4
pubmed: 36088446
Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE. Hypercholesterolemia and prostate cancer: a hospital-based case–control study. Cancer Causes Contr. 2008;19:1259–66.
doi: 10.1007/s10552-008-9197-7
Jiang Q, Wang L, Jin M, Shou Y, Zhu H, Li A. The clinical value of lipid abnormalities in early stage cervical cancer. Int J Gen Med. 2022;15:3903–14 Epub 2022/04/19.
doi: 10.2147/IJGM.S352934
pubmed: 35431573
pmcid: 9012499
Sitarz K, Czamara K, Bialecka J, Klimek M, Szostek S, Kaczor A. Dual switch in lipid metabolism in cervical epithelial cells during dysplasia development observed using Raman microscopy and molecular methods. Cancers. 2021;13(9):1997.
doi: 10.3390/cancers13091997
pubmed: 33919178
pmcid: 8122332
Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 2009;100(9):1369–72.
doi: 10.1038/sj.bjc.6605007
pubmed: 19352381
pmcid: 2694429
Sun Y, Meng H, Jin Y, Shi X, Wu Y, Fan D, et al. Serum lipid profile in gynecologic tumors: a retrospective clinical study of 1,550 patients. Eur J Gynaecol Oncol. 2016;37(3):348–52.
pubmed: 27352562
Ulmer H, Bjørge T, Concin H, Lukanova A, Manjer J, Hallmans G, et al. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me–Can). Gynecol Oncol. 2012;125(2):330–5.
doi: 10.1016/j.ygyno.2012.01.052
pubmed: 22330614
Luo X, Zhao X, Cheng C, Li N, Liu Y, Cao Y. The implications of signaling lipids in cancer metastasis. Exp Mol Med. 2018;50(9):1–10.
doi: 10.1038/s12276-018-0150-x
pubmed: 30242147
pmcid: 6035243
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.
doi: 10.1126/science.1160809
pubmed: 19460998
pmcid: 2849637
Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab. 2012;16(4):414–9.
doi: 10.1016/j.cmet.2012.09.002
pubmed: 23000402
pmcid: 3466394
Munir R, Lisec J, Swinnen JV, Zaidi N. Lipid metabolism in cancer cells under metabolic stress. Br J Cancer. 2019;120(12):1090–8.
doi: 10.1038/s41416-019-0451-4
pubmed: 31092908
pmcid: 6738079
Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 2017;20(3):303–14 e5.
doi: 10.1016/j.stem.2016.11.004
pubmed: 28041894
Igal RA. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis. 2010;31(9):1509–15.
doi: 10.1093/carcin/bgq131
pubmed: 20595235
Yan S, Cui S, Ke K, Zhao B, Liu X, Yue S, et al. Hyperspectral stimulated Raman scattering microscopy unravels aberrant accumulation of saturated fat in human liver cancer. Anal Chem. 2018;90(11):6362–6.
doi: 10.1021/acs.analchem.8b01312
pubmed: 29757615
Wang Y-P, Lei Q-Y. Metabolic recoding of epigenetics in cancer. Cancer Commun. 2018;38(1):1–8.
Jones PA. Functions of D.N.A. methylation: islands, start sites, gene bodies and beyond. Nature Rev Genet. 2012;13(7):484–92.
doi: 10.1038/nrg3230
pubmed: 22641018
Lin F, Zheng R, Yu C, Su Y, Yan X, Qu F. Predictive role of serum cholesterol and triglycerides in cervical cancer survival. Int J Gynecol Cancer. 2021;31(2).
Sun W, Qin X, Zhou J, Xu M, Lyu Z, Li X, et al. Mitochondrial DNA copy number in cervical exfoliated cells and risk of cervical cancer among HPV-positive women. BMC Women’s Health. 2020;20:1–7.
doi: 10.1186/s12905-020-01001-w